Multiple-Distributor System in China and Expansion of Sales Offices in Emerging Markets
First written in FY2016. 7 of 21 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-05-15.
- 2026-05-15OtherFinancial results presentation
「China: inventory replenishment was brought forward due to changes in the distribution network in both the prior and current periods, but performance remained strong even excluding this impact」
In China, inventory replenishment was brought forward due to changes in the distribution network, while performance remained strong even excluding this effect. - FY2026-H1Updated the change in non-cardiovascular products in ChinaAnnual report
「In the non-cardiovascular field, although cerebrovascular and abdominal vascular products declined in the Chinese market, sales increased due to growth in peripheral and abdominal vascular products in the United States, Europe and Asia.」
Although neurovascular and abdominal vascular products declined in the Chinese market, the overall non-cardiovascular field generated higher sales because of growth in peripheral and abdominal vascular products in other regions. - FY2025AdvancedAnnual report
「In the Chinese market, mainly for our own-brand products, local distributors sell products through a logistics platform, and we have secured a high market share, particularly in cardiovascular products. Even as the market environment changes, including the introduction of bidding systems, we will seek further market share and earnings growth by building cooperative relationships with multiple local distributors through the logistics platform, strengthening our support structure, deepening relationships with physicians, launching new products and enhancing sales activities.」
The company specified a cooperative and support structure with multiple distributors through a logistics platform in China, developing a sales strategy combining responses to the bidding system, relationships with physicians and new product launches. - FY2024Updated the increase in transactions with China.Annual report
「Sales of medical components increased, as domestic sales benefited from higher sales of endoscopy-related components and overseas sales benefited from the stronger foreign currency and an increase in transactions with China.」
The increase in transactions with China was identified as a factor contributing to higher overseas sales of medical components. - FY2024-Q3Updated the increase in abdominal products in the Chinese market.Annual report
「In the non-cardiovascular field, net sales increased in all regions, driven by the effects of new products such as CROSSLEAD in the U.S. peripheral vascular product market and growth in abdominal products in the U.S. and Chinese markets.」
Growth in abdominal products was reported in the Chinese market, and Medical Business sales in China were ¥17,589 million. This was an increase from ¥15,236 million in the same period of the previous year. - FY2023-Q2Specified a partial decline in sales due to inventory adjustments by distributors in China.Annual report
「In overseas markets, the cardiovascular field performed very strongly in all regions, led by PCI guidewires and penetration catheters. In the non-cardiovascular field, sales declined in China due to inventory adjustments by distributors, but performed well in other regions, resulting in higher sales.」
In China, the non-cardiovascular field declined due to inventory adjustments by distributors, while overseas sales increased because of growth in other regions. - FY2023-Q1AdvancedAnnual report
「As measures toward achieving this, during the three months ended the first quarter, we entered into ① a basic agreement for the exclusive distribution in Japan of Penumbra Inc.’s (U.S.) thrombus aspiration devices for peripheral vessels, ② an exclusive distribution agreement in China for DK MEDTECH (Suzhou) Co., Ltd.’s “DK Score coronary scoring balloon dilatation catheter,” and ③ issued the Group’s first “Integrated Report 2022.”」
The company signed an exclusive distribution agreement for DK MEDTECH's DK Score coronary scoring balloon dilatation catheter in the Chinese market, adding a new product to its product sales network in China. - FY2022Added a response to China's centralized procurement bidding system.Annual report
「Although the Chinese market continues to be affected by lower procedure volumes resulting from COVID-19, we will continue to steadily pursue sales growth by rebuilding our distributor network in line with our strategic response to the centralized procurement bidding system.」
The company outlined a policy of rebuilding its distributor network in response to China's centralized procurement bidding system, in addition to its existing multiple-distributor system and support through its Beijing subsidiary. - FY2021RestatedAnnual report
「Going forward, while taking market conditions into account, we will seek further earnings growth by increasing the number of distributors, enhancing marketing and sales activities through our consolidated subsidiary 朝日英達科貿(北京)有限公司, and strengthening our support structure closely aligned with local distributors.」
The company continues its policy of increasing the number of distributors in China, conducting sales activities through its Beijing subsidiary and expanding earnings through support for local distributors. - FY2021-Q3AdvancedAnnual report
「In overseas markets, the impact of lower procedure volumes due to COVID-19 remains. However, sales of PTCA guidewires and penetration catheters in the cardiovascular field increased, supported by stronger sales promotion activities in China and the promotion of direct sales in South Korea.」
The company said that stronger sales promotion activities in China and the promotion of direct sales in South Korea led to higher sales of cardiovascular products. - FY2020RestatedAnnual report
「Since the fiscal year ended June 2016, we have been transitioning to a multiple-distributor system, mainly for products in the cardiovascular field, and are continuing to expand market share. Going forward, while taking market conditions into account, we will seek further earnings growth by increasing the number of distributors, enhancing marketing and sales activities through our consolidated subsidiary 朝日英達科貿(北京)有限公司, and strengthening our support structure closely aligned with local distributors.」
The company continues its policy of using multiple distributors in China, increasing the number of distributors and providing sales support through its Beijing subsidiary. - FY2020-Q3RestatedAnnual report
「In addition, to strengthen sales and marketing activities, the company gradually began direct sales in France, decided to shift to direct sales in South Korea, established EU and Russian subsidiaries (ASAHI INTECC EUROPE B.V. and ASAHI INTECC CIS LLC), and opened a Guangzhou office of 朝日英達科貿(北京)有限公司 in the Chinese market.」
The company reaffirmed the opening of a Guangzhou office of 朝日英達科貿（北京）有限公司 as a measure to strengthen sales and marketing activities in the Chinese market. - FY2020-Q2AdvancedAnnual report
「In addition, to strengthen sales and marketing activities, the company gradually began direct sales in France, decided to establish a local subsidiary in Russia, and opened a Guangzhou office of 朝日英達科貿(北京)有限公司 in the Chinese market.」
The company opened a Guangzhou office of 朝日英達科貿（北京）有限公司 to strengthen sales and marketing activities in the Chinese market. It also decided to establish a local subsidiary in Russia. - FY2020-Q1AdvancedAnnual report
「Opened 朝日英達科貿(北京)有限公司's Guangzhou office to strengthen sales and marketing activities in China's expanding market.」
The company opened a Guangzhou office of 朝日英達科貿（北京）有限公司 to strengthen sales and marketing activities in the Chinese market. - FY2019RestatedAnnual report
「Since the fiscal year ended June 2016, we have been transitioning to a multiple-distributor system, mainly for products in the cardiovascular field, and are continuing to expand market share. Going forward, while taking market conditions into account, we will seek further earnings growth by increasing the number of distributors, enhancing marketing and sales activities through our consolidated subsidiary 朝日英達科貿(北京)有限公司, and strengthening our support structure closely aligned with local distributors.」
The company continues its multiple-distributor system in China, increases the number of distributors and provides sales support through its Beijing subsidiary. - FY2018RestatedAnnual report
「Since the fiscal year ended June 2016, we have been transitioning to a multiple-distributor system, mainly for products in the cardiovascular field, and are continuing to expand market share. Going forward, while taking market conditions into account, we will seek further earnings growth by increasing the number of distributors, enhancing marketing and sales activities through our consolidated subsidiary 朝日英達科貿(北京)有限公司, and strengthening our support structure closely aligned with local distributors.」
The company continues to pursue a multiple-distributor system in China, an increase in the number of distributors and stronger support through its Beijing subsidiary. - FY2017RestatedAnnual report
「Since the fiscal year ended June 2016, we have been transitioning to a multiple-distributor system, mainly for products in the cardiovascular field, and are continuing to expand market share.」
The company said it would continue its multiple-distributor system in China and distributor support through its Beijing subsidiary, while strengthening its sales organization in emerging markets such as India, Brazil and Russia. - FY2017-Q3AdvancedAnnual report
「In the Chinese market, we changed our sales strategy for products in the cardiovascular field to a model involving sales through multiple distributors. During the nine months ended 31 December of the current fiscal year, the number of consolidated subsidiaries engaged in product sales and other activities in the Medical Business increased, including ASAHI INTECC LATIN LTDA.」
The company continued shifting to a multiple-distributor sales model in China and added the Latin American sales subsidiary ASAHI INTECC LATIN LTDA. to the scope of consolidation. - FY2017-Q2RestatedAnnual report
「Because the company changed its sales strategy in the Chinese market in July 2016 to a system of selling through multiple distributors, order volumes increased substantially and have performed well.」
The company has reiterated that it shifted to a multiple-distributor system in the Chinese market from July 2016 and that order volumes increased substantially. - FY2017-Q1AdvancedAnnual report
「The company revised its sales strategy for cardiovascular products in the Chinese market and, from the first three months of the current consolidated fiscal year, changed to a system of selling through multiple distributors. Following this change, order volumes increased substantially and have performed well.」
It states that the company shifted to a multiple-distributor system in the Chinese market and that order volumes increased substantially after the change. - FY2016First statedAnnual report
「Going forward, the company will pursue a shift to a multiple-distributor system centered on cardiovascular products, enhance marketing and sales activities through the consolidated subsidiary 朝日英達科貿（北京）有限公司, and strengthen its support structure by working closely with local distributors, with the aim of further increasing market share.」
In China, the company is increasing the number of distributors and advancing support through its Beijing subsidiary. It also plans to open offices in Brazil, Russia, and other markets, following India and South Korea.